Australian Progen CEO Says Oncology Pipeline Advances Despite Troubles
This article was originally published in PharmAsia News
Executive Summary
Australia's Progen Pharmaceuticals says it is staying on track and pushing its anti-cancer drugs through its pipeline despite several upheavals that have plagued it for the past six months. CEO Justus Homburg presented an upbeat view of the company's prospects, such as its metastatic melanoma drug now about to enter Phase II trials. Progen also says its small-molecule heparanese inhibitor discovery program also is getting encouraging results. Progen has been under attack by two separate groups of shareholders, including another cancer drug developer with stock, Cytopia, which also helped derail a Progen merger with Avexa. (Click here for more